CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

U.S. Confirmatory Registration Study expected to begin Summer 2026 Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of